Amgen Inc.

Neumora Therapeutics, Inc.

Zhihua Ma

Jonathan B Houze

Julio Cesar Medina

Paul John Dransfield

Zice Fu

Vatee Pattaropong

Julie Anne Heath

David John Kopecky

Xiaoqi Chen

Xiaodong Wang

Su-Jen Lai

Richard V Connors

Steven H Olson

Nobuko Nishimura

Jeffrey Thomas Mihalic

Jeffrey Deignan

Mikkel V Debenedetto

Gayathri Swaminath

Ning Chen

Yinhong Chen

Aarif Yusuf Khakoo

Xiaohui Du

Alan C Cheng

Wen-Chen Yeh

Lawrence R McGee

Frank Kayser

Matthew R Kaller

Jiwen Liu

Daniel B Horne

Yingcai Wang

Kevin Chao Yang

Ted Charles Judd

James S Harvey

Simon J Hedley

Michael J Schmitt

Rajiv Sharma

Robert P Farrell

Jinqian Liu

Liusheng Zhu

Hilary Plake Beck

XianYun Jiao

SuJen Lai

Wang Shen

Daqing Sun

Xuelei Yan

Ming Yu

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Brian M Fox

Sean P Brown

Michael D Bartberger

John Eksterowicz

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Darin J Gustin

Zhihong Li

Zhongyu Wang

Joel McIntosh

Marc Vimolratana

Jiasheng Fu

Yihong Li

Philip M Roveto

Jiang Zhu

Malgorzata Wanska

Michelle Akerman

Wei Qiu

Ying Sun

Ankit Sharma

Steven Howard Olson

Anne-Marie Beausoleil

Jian Luo

Dustin L McMinn

Jonathan Dante Low

Brian Stuart Lucas

Charles Kreiman

Lars V Heumann

Todd J Kohn

Dilinie Fernando

Jian Zhang

Michael W Gribble, Jr

Xin Huang

Benjamin Fisher

Stephen J Shuttleworth

Daniel C H Lin

Jeffrey D Reagan

Philip Dean Ramsden

Ryan Hudson

Paul Dransfield

John Stellwagen

Brian Sparling

Matthew Irvine Brown

Kevin Yang

An-Rong Li

James C Harvey

David C Moebius

Christine Weathers

The present disclosure relates to compounds of Formula (I),

Methods of treating neurological disorders

The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula I, pharmaceutically acceptable salts thereof, tautomers thereof, pharmaceutically acceptable salts of the tautomers, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein. 

Fused triazole agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Growing community of inventors

Lexington, MA, United States of America

Zhihua Ma